Be a part of a new era
in cellular therapy

for the potential treatment of relapsed/refractory AML

Many advancements have been made in the treatment of cancer, including a recent focus to develop treatments that activate the immune system to fight cancer, called immunotherapies.

Despite advances in the management of AML, additional therapies are needed to overcome the limitations of current therapies, including treatments no longer working and overall toxicity of therapies.

Rubius Therapeutics is developing an investigational potential treatment option, RTX-240, for relapsed acute myeloid leukemia or refractory AML using the body’s own immune system to attack cancer. RTX-240 is an engineered red blood cell that is designed to activate the immune system against cancer.

About RTX-240
RTX-240 is an investigational cellular therapy that aims to activate the immune system to fight cancer.

RTX-240 is an engineered red blood cell that is being evaluated in a Phase 1/2 clinical trial for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.

RTX-240 is an investigational cellular therapy that is designed to activate and amplify the effects of immune system cells called natural killer (NK) cells and T cells, which play a role in killing tumor cells. The Phase 1/2 clinical study of RTX-240 has three separate Phase 1 arms: an ongoing monotherapy dose escalation arm in adults with relapsed/refractory or locally advanced solid tumors, an ongoing monotherapy dose escalation arm in adults with relapsed/refractory acute myeloid leukemia, and a combination therapy dose escalation arm with pembrolizumab in adults with relapsed/refractory or locally advanced solid tumors. The monotherapy arm of the trial in advanced solid tumors includes a Phase 2 expansion in specified tumor types.

Learn more about RTX-240

RTX‑240 Phase 1/2 Clinical Trial

Complete a patient screener to see if you may be able to participate.

Patient Screener

Patient Screener

Sign up to learn more about Red Cell Therapeutics™ and cancer clinical trials.

Sign Up Form

Sign Up Form

Rubius Therapeutics is now enrolling patients in a phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors, or relapsed acute myeloid leukemia (AML) or refractory AML.

Complete a patient screener to see if you may be able to participate.

Thank you! You may be a potential candidate for a study doctor to evaluate for participation in this study.

If you wish to be connected to a clinical trial site in the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine your interest and if you would meet the requirements to be evaluated by a study doctor for screening in the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.

NEXT

Thank you!

Based on the information provided, you may not meet the requirements for this study. We want to thank you for your interest – patient volunteers and their family members are an essential part of the development of new therapies for cancer. If you still would like to learn more about Red Cell Therapeutics™ and receive updates about clinical trials that might be available in your area for the potential treatment of cancer for yourself or a loved one, sign up here.

Thank you!

You may be a potential candidate for a study doctor to evaluate for participation in this study. If you wish to be connected to a clinical trial site for the RTX-240 study, please fill in your contact information below. Someone from our Patient Advocacy Team may reach out to you to determine if you would meet the requirements to be evaluated by a study doctor for screening for the RTX-240 study. Your personal information, including information entered below and discussed with our Patient Advocacy Team, may then be shared with a clinical study site.